case_images: PMC8133855_01
case_images: Severe erosions and presence of bullous lesions of the oral mucosa.
case_images: CRIN2021-9940293.001.jpg
case_images: PMC8133855_01_CRIN2021-9940293.001.jpg
case_images: fig1
case_images: The patient had initially been referred to dermatology after developing bullous lesions and erosions of her oral mucosa and to a lesser degree of her skin (Figure 1).
case_images: Oral prednisone dose over time. The arrow represents initiation of rituximab.
case_images: CRIN2021-9940293.002.jpg
case_images: PMC8133855_01_CRIN2021-9940293.002.jpg
case_images: fig2
case_images: Mycophenolic acid (MPA) was initiated to address both MN and MMP and titrated to reach 1080 mg twice daily, with a progressive tapering of oral glucocorticoids (Figure 2).
case_images: Serum albumin over time (top panel) and 24-hour proteinuria over time. The arrow represents infusions of rituximab.
case_images: CRIN2021-9940293.003.jpg
case_images: PMC8133855_01_CRIN2021-9940293.003.jpg
case_images: fig3
case_images: Initial laboratory follow-up showed reduced proteinuria (Figure 3). On assessment 4 months after starting rituximab, clinical remission was observed, with absence of edema, resolution of cutaneous symptoms, and reduction of proteinuria (Figure 3).